Biotech News

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Virios Therapeutics (VIRI)Virios Therapeutics2025-12-22 15:15 ESTClinical readout

VIRI (VIRI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is viri.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VIRIVirios Therapeutics2026-07-20 12:30 EST

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

VIRIVirios Therapeutics2026-02-02 13:30 EST

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

ANTXAN2 Therapeutics2026-03-31 11:00 EST

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

IMNNImunon2026-07-21 13:00 EST

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

OGENOragenics2026-05-05 12:30 EST

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

OGENOragenics2026-03-12 12:30 EST

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

MBRXMoleculin Biotech, Inc.2026-07-31 12:10 EST

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

MBRXMoleculin Biotech, Inc.2026-06-30 12:30 EST

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

View all latest news

Virios Therapeutics

Virios Therapeutics is a biotechnology company focused on viral-trigger and inflammation biology, with an emphasis on chronic disease programs. Its story is built around a narrow disease hypothesis and early-stage development.

Recent company news

VIRIVirios Therapeutics2026-07-20 12:30 EST

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

VIRIVirios Therapeutics2026-06-30 12:45 EST

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

VIRIVirios Therapeutics2026-05-18 12:45 EST

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

VIRIVirios Therapeutics2026-05-14 12:30 EST

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

VIRIVirios Therapeutics2026-05-07 12:30 EST

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States